Advanced Cell Diagnostics

Bio-Techne has also agreed to pay up to an additional $75 million if Advanced Cell Diagnostics achieves certain milestones.

The companies plan to combine ACD's RNAscope in situ hybridization assays with Leica's clinical advanced staining instruments to develop tissue-based diagnostics.

The company will use the financing to accelerate its entry into the research and clinical diagnostics markets and to launch new technology platforms.

Flagship Bio is using ACD's RNAscope and customizing and optimizing the technology for use in CLIA clinical trials with "several large pharmaceutical clients."

Merrimack will use RNAscope to select patients with heregulin-positive, locally advanced metastatic NSCLC for a Phase II clinical trial for the drug candidate MM-121. 

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics announced today a preferred partnership agreement with Dundee, UK-based MicroMatrices to develop applications of its RNAscope technology.

NEW YORK (GenomeWeb) – Advanced Cell Dx today announced Edinburgh, Scotland-based CRO Aquila-Histoplex as the first accredited RNAscope Certified Service Provider in Europe.

NEW YORK (GenomeWeb) – A recent evaluation of FDA-approved molecular HPV screening assays from Roche, Hologic, and Qiagen has found that the three tests showed variations in which samples tested positive or negative.

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics today announced it has been awarded a two-year $1.4 million grant from the National Cancer Institute to develop and validate a diagnostic test for differentiating various B-cell non-Hodgkin lymphomas from benign lymphoproliferative diseases.

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics today announced the formation of a European subsidiary, to be operational next month.

Pages

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.